(News Bulletin 247) – UBS reaffirms its ‘buy’ recommendation on Sartorius, but lowers its target price from 500 to 470 euros, a new target which still harbors a potential for growth of 32% for the title of the German group.
The broker underlines in the summary of its note, that after showing confidence despite a weak first quarter, the supplier of equipment and services to the pharmaceutical industry has finally lowered its objectives.
“The objectives for 2025 remain in place, which implies a normalization to intervene at some point”, recognizes UBS which considers however that “the visibility remains bad” on the file.
Copyright (c) 2023 News Bulletin 247. All rights reserved.
I have over 8 years of experience working in the news industry. I have worked as a reporter, editor, and now managing editor at 247 News Agency. I am responsible for the day-to-day operations of the news website and overseeing all of the content that is published. I also write a column for the website, covering mostly market news.
